

# CITATION REPORT

List of articles citing

## PDE-5 Inhibitors for BPH-Associated LUTS

DOI: 10.2174/138945011611151013164756  
Current Drug Targets, 2015, 16, 1180-6.

**Source:** <https://exaly.com/paper-pdf/88185558/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Combination Pharmacological Treatments for LUTS. <i>Current Drug Targets</i> , <b>2015</b> , 16, 1162-4	3	1
6	Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?. <i>Current Urology Reports</i> , <b>2016</b> , 17, 46	2.9	12
5	Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases. <i>Cardiovascular Drugs and Therapy</i> , <b>2019</b> , 33, 119-128	3.9	10
4	Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 T cells in benign prostatic hyperplasia. <i>Prostate</i> , <b>2019</b> , 79, 909-919	4.2	10
3	Re-evaluation of the immunohistochemical distribution of isoforms of nitric oxide synthase in the human prostate: A light and electron microscopical study. <i>Andrologia</i> , <b>2021</b> , 53, e14098	2.4	
2	Current Treatment for Benign Prostatic Hyperplasia. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2020</b> , 117, 843-854	2.5	6
1	The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia. <b>2023</b> , 24, 2870		0